Bacterial extract OM-85 BV protects mice against experimental chronic rhinosinusitis.
OBJECTIVE
To investigate the therapeutic effects of OM-85 BV as an adjunctive treatment on experimental chronic rhinosinusitis (CRS) in mice.


METHODS
Female BALB/c mice aged 8-12 weeks were sensitized and administrated by intranasal Aspergillus fumigatis (AF) three times per week for 1 week, 3 weeks, 2 months and 3 months (n = 10 each time point). The mice were randomly and equally assigned to four groups: normal control group, model group, OM-85-BV plus amoxicillin group, and isolated amoxicillin group. Inflammatory changes were determined by hematoxylin-eosin (HE) staining. The expression levels of suppressor of cytokine signaling (SOCS) 1, SOCS3, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ in samples were assessed by using real-time PCR (RT-PCR) and Western blotting.


RESULTS
There were significantly inflammatory and structural changes between the model and other groups. Compared to the model group, the mRNA expression levels of SOCS1, SOCS3, TNF-α, and IFN-γ were significantly decreased in OM-85-BV plus amoxicillin group and isolated amoxicillin group, along with the protein levels.


CONCLUSIONS
The bacterial extract OM-85 BV is a low-cost alternatively adjunctive drug to treat CRS with simple oral administration, good safety, and few side effects.
Department of Otolaryngology, Weifang People's Hospital Weifang, P. R. China ; Department of Otolaryngology, Qilu Hospital of Shandong University Jinan, P. R. China.
Yanli
Y
Tao
Department of Otolaryngology, Weifang People's Hospital Weifang, P. R. China.
Tiejun
T
Yuan
Department of Otolaryngology, Weifang People's Hospital Weifang, P. R. China.
Xuechang
X
Li
Department of Otolaryngology, Weifang People's Hospital Weifang, P. R. China.
Shuqin
S
Yang
Department of Otolaryngology, Weifang People's Hospital Weifang, P. R. China.
Fanping
F
Zhang
Department of Otolaryngology, Qilu Hospital of Shandong University Jinan, P. R. China.
Li
L
Shi
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000284:Administration, Oral; D000658:Amoxicillin / Q000494:pharmacology; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology; D001228:Aspergillosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000276:immunology / Q000472:pathogenicity; D002457:Cell Extracts / Q000008:administration & dosage / Q000494:pharmacology*; D002908:Chronic Disease; D004195:Disease Models, Animal; D005260:Female; D018836:Inflammation Mediators / Q000378:metabolism; D019570:Inhalation Exposure; D007371:Interferon-gamma / Q000235:genetics / Q000378:metabolism; D008807:Mice, Inbred BALB C; D012333:RNA, Messenger / Q000378:metabolism; D012220:Rhinitis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D012852:Sinusitis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D000071222:Suppressor of Cytokine Signaling 1 Protein; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins / Q000235:genetics / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D000658:Amoxicillin; D000935:Antifungal Agents; D002457:Cell Extracts; D018836:Inflammation Mediators; D007371:Interferon-gamma; D012333:RNA, Messenger; D000071222:Suppressor of Cytokine Signaling 1 Protein; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins; D014409:Tumor Necrosis Factor-alpha; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates; C491590:Socs1 protein, mouse; C491411:Socs3 protein, mouse
IFN-γ; OM-85-BV; SOCS1; SOCS3; TNF-α